venBio Partners — Full Portfolio

Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).

BiotechDeep TechHealthtechDurham, US

MKMATTHEW KANE(Executive Officer, Director)JSJeff Smith(Co-founder)inDJDerek Jantz(Co-founder)inTODD MELBY(Executive Officer)inMAMichael Amoroso(President, Chief Executive Officer)in

Board seatRARobert Adelman· per SEC Form D

Co-investorsAGage1AGAgent CapitalALAliment CapitalBRBrace PharmaF-F-Prime CapitalOCOCV Partners+6 more

Achieve is a specialty pharmaceutical company developing and commercializing cytisinicline as a treatment for nicotine dependence, aimed at helping people who smoke quit.

BiotechHealthtechVancouver, B.C., US

Anthony Clarke(Executive Officer)RSRichard Stewart(Co-founder & Director (former President and CEO))CJCindy Jacobs(Executive Officer, Director)inJXJaime Xinos(Executive Officer)inJBJohn Bencich(Executive Officer, Director)inAndrew D. Goldberg(Chief Executive Officer & Director)in

Co-investorsLILifeSci Venture PartnersVIVivo CapitalFRFrazier Life Sciences

Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.

AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US

MBMartin Babler(President, Chief Executive Officer and Chairman of the Board)inMBMark Bradley(Chief Development Officer)inKBKolbot By(SVP, Head of Technical Operations)inJDJack Danilkowicz(Chief Commercial Officer)inJDJörn Drappa(Chief Medical Officer)inDMDavid M Goldstein(Chief Scientific Officer)in

Co-investorsFOForesite CapitalGEGeneral AtlanticHBHBM Healthcare InvestmentsHBHBM PartnersNENextech InvestOROrbiMed+4 more

AstraZeneca develops and markets pharmaceutical products, vaccines, and biologics across oncology, cardiovascular disease, respiratory and immunology, and rare disease areas, serving patients and healthcare providers globally.

Cambridge, GB

Co-investors+N+ND Capital

ALX Oncology develops therapies for cancer treatment, operating in the biotechnology and medical technology sectors.

BiotechHealthtechMedical Devices

CGCorey Goodman(Chairman)inJLJason Lettmann(Chief Executive Officer)in

Co-investorsLILightstone VenturesAGage1FOForesite CapitalHBHBM Healthcare InvestmentsHBHBM PartnersLOLogos+1 more

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.

BiotechHealthtechMedical DevicesCambridge, US

Elisabet de los Pinos, Ph.D.(Executive Officer, Director)EDElisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)Lewis Geffen(Executive Officer)

Co-investorsADAdvent Life SciencesCHChiesi VenturesCOColumbus Venture PartnersDRDroia VenturesFOForesite CapitalJAJazzya Investments+6 more

Compass Therapeutics uses proprietary antibody discovery platforms to generate and screen diverse panels of monoclonal and multispecific antibodies, aiming to identify synergistic therapeutic combinations.

BiotechHealthtechCambridge, US

STSchuetz Thomas(Executive Officer, Director)inEAErrik Anderson(Executive Officer, Director)inTJThomas J. Schuetz(Executive Officer, Director)inVBVered Bisker-Leib(Executive Officer)inBarry Shin(Chief Financial Officer)inNLNeil Lerner(Senior Vice President, Chief Accounting Officer)in

Co-investorsALAlumni VenturesBIBioBritF-F-Prime CapitalFOForesite CapitalGVGV (Google Ventures)OROrbiMed+3 more

Data I/O provides device programming systems and services for semiconductors including MCUs, UFS, eMMC, NAND flash, and security ICs, along with security provisioning like cryptographic key injection and device identity.

Advanced ManufacturingHardwareSemiconductors

WWWilliam Wentworth(Chief Executive Officer, President, and Director)in

Immuron is an Australian biopharmaceutical company developing and commercialising targeted polyclonal antibodies aimed at addressing unmet medical needs.

BiotechDigital HealthWellness & Fitness

Steven Lydeamorein

Co-investorsSISilver Lake Partners

Johnson & Johnson develops prescription medicines and medical technology across areas including oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopaedics, surgery, and vision.

BiotechHealthtechMedical DevicesNew Brunswick, US

EMEdward Mead JohnsonJWJames Wood JohnsonRWRobert Wood Johnson IJDJoaquin DuatoinJ. Duato(Chief Executive Officer)

Co-investorsAIAisling CapitalATAtlas VentureNANaviMed CapitalPOPortland Seed FundSPSPRINGROCK VENTURESTHThe Column Group

Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.

AI & Machine LearningBiotechDeep TechMedical Devices

MMMathai Mammen(CEO, President and Chairman)in

Co-investorsARARCH Venture PartnersCACatalio Capital Management, LPDEDeerfield Management CompanyFOForesite CapitalFRFrazier Life SciencesGEGeneral Catalyst+9 more

Seaport Therapeutics develops therapeutics and medicines.

BiotechMental HealthBoston, US

DZDaphne Zohar(Founder, CEO & Board Member)inSPSteven Paul, M.D.(Founder, Board Chair)inMichael Chen, Ph.D.(Co-Founder, Chief Scientific Officer)MCMichael Chen(Executive Officer)inLGLana Gladstein(Executive Officer)inALAntony Loebel(Executive Officer)in

Co-investorsARARCH Venture PartnersFOForesite CapitalGEGeneral AtlanticHAHAWKTAILPUPureTech HealthSOSofinnova Ventures+4 more

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.

BiotechWaltham, US

John Pallies(Executive Officer)inAMArlene Morris(Executive Officer, Director)inMAMichael A. Metzger(Chief Executive Officer)inKAKeith A. Goldan(Chief Financial Officer)in

BoardDPDennis Podlesak(Director)inIvor Royston(Director)

Co-investorsAIAisling CapitalATATEM Capital FundAVAvoro Capital AdvisorsBIBioBritDEDelos CapitalECEcoR1 Capital+6 more

Tenaya Therapeutics is a biotechnology company focused on discovering and developing therapies for heart disease.

BiotechHealthtechSouth San Francisco, US

DSDeepak Srivastava, M.D.(Scientific Founder)inEOEric Olson, Ph.D.(Scientific Founder)BRBruce R. Conklin, M.D.(Scientific Founder)inSDSheng Ding, Ph.D.(Scientific Founder)SHSaptarsi Haldar, M.D.(Scientific Founder)inEric Hyllengren(Chief Financial Officer)in

Co-investorsGVGV (Google Ventures)RARA CapitalTHThe Column Group

Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.

BiotechDeep TechBoston, US

SVShane V. Hegarty(Chief Scientific Officer & Co-Founder)inJSJoanna Stanicka(Chief Executive Officer, President & Co-Founder)inJIJeff Imbaro(Chief Operating Officer)inTSTiasha Shafiq(Chief of Staff)in

BoardC.Corey . Goodman(Director)inJLJonathan Leff(Director)in

Co-investorsSOSofinnova VenturesMRMRL Ventures FundCICivilization Ventures Management, LlcCRCreative Destruction Lab (CDL)HAHatteras Venture PartnersIAIaso Ventures+8 more

Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform.

BiotechDigital HealthMedical DevicesRedwood City, US

ECEmmett Cunningham(Executive Officer, Director)inMark Bachleda(Executive Officer, Director)inRVRobert Vitti(Executive Officer)inOSOliver Stauch(Executive Officer)inCWConrad Wang(Director)in

BoardDEDan Estes(Director)in

Co-investorsFRFrazier Life SciencesHEHealthQuest CapitalRARA CapitalVEvenBio Global Strategic

NorthSea Therapeutics is a clinical-stage biopharmaceutical company developing oral fatty acid-derived therapies for liver and metabolic diseases, including intestinal failure-associated liver disease (IFALD), severe hypertriglyceridemia, and MASH.

BiotechDigital HealthHealthtech

Co-investorsNENew Science VenturesYSYsios CapitalBGBGVNONovo HoldingsBIBioGeneration VenturesSOSofinnova Ventures+1 more

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.

BiotechBerkeley, US

Allison J. Hulme(CEO & President)inJKJohn Kincaid(Chief Scientific Officer)inDRDavis Ryman(Executive Officer)inMZMicah Zajic(Executive Officer)inIan Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)

Board seatRGRichard Gaster· per SEC Form D

Co-investorsCOCoastCapCTCTI Life Sciences Fund L.P.FEFelix JahnFJFJ LabsLULuma GroupSOSofinnova Ventures+2 more

NASDAQ-listed company developing therapies for complement cascade-driven diseases in haematology, ophthalmology, and nephrology.

BiotechCrestwood, US

Pascal Deschatelets(Executive Officer)inCedric Francois(Executive Officer, Director)in

BoardGerald Chan(Director)Stephanie O'Brien(Director)Alec Machiels(Director)A. Sinclair Dunlop(Director)

Board seatRARobert Adelman· per SEC Form D

Co-investorsAVAvoro Capital AdvisorsEMEMBL VenturesEPEpidarex CapitalF-F-Prime CapitalKEKeyhorse CapitalSOSofinnova Ventures+1 more

Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.

BiotechHealthtechSouth San Francisco, US

JWJonathan Wall(Executive Officer)inSpencer Guthrie(Executive Officer)MTMark Timney(Executive Officer, Director)inBenson Fong(Executive Officer)RKRahul Kakkar(Director)inGreg Bell(Executive Officer)

Board seatCGCorey GoodmanRGRichard Gaster· per SEC Form D

Co-investorsALAlpha Wave GlobalBIBioBritLILifeSci Venture PartnersJAJanus Henderson InvestorsREREDMILESASamsara BioCapital+2 more

Impel Pharmaceuticals develops therapies for diseases with high unmet medical needs by pairing established drugs with its proprietary upper-nasal drug delivery technology.

BiotechHealthtechMedical DevicesSeattle, US

JDJohn D. Hoekman(Executive Officer, Director)in

BoardMichael Hite(Director)Stewart Parker(Director)

Board seatARAaron Royston· per SEC Form D · $37.3M raise · filed Dec 2016

Co-investors5A5AM VenturesB B Capital GroupVEvenBio Global StrategicWEWestlake Village BioPartners

Acquired by Lisata Therapeutics alongside a $225 million concurrent private placement.

BiotechSan Francisco, US

Mark Joing(Executive Officer)inChristine Garrett(Executive Officer)inJosh Lehrer(Executive Officer, Director)inEthan Weiss(Executive Officer)inCaitlin Murray(Executive Officer)

BoardJeff Tong(Director)

Board seatARAaron Royston· per SEC Form D

Co-investorsALAlpha Wave GlobalSOSofinnova VenturesTHThird Rock VenturesFOForbion

San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.

BiotechSan Diego, US

Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)

BoardKBKristina Burow(Director)inRHRichard Heyman(Director)inANAmir Nashat(Director)in

Board seatRARobert Adelman· per SEC Form D · $37.8M raise · filed Nov 2016

Co-investorsAGage1ECEcoR1 CapitalLALAVLILifeSci Venture PartnersLILilly Asia VenturesNENew Enterprise Associates (NEA)+8 more

RayzeBio develops radiopharmaceutical therapies for cancer treatment.

BiotechHealthtechMedical DevicesSan Diego, US

KSKen Song(Executive Officer, Director)inBHBen Hickey(President)inAbhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)

Board seatARAaron Royston· per SEC Form D

Co-investorsLILifeSci Venture PartnersSASamsara BioCapitalSCScion Life SciencesSOSofinnova VenturesTCTCG CrossoverVEVersant Ventures+4 more

BiotechSan Francisco, US

Curt Bradshaw(Executive Officer, Director, Promoter)inFrank Muhlenbeck(Mr. Muhlenbeck is a Manager of the Issuer.)

BoardCGCorey Goodman(Executive Officer, Director, Promoter)inSteven Dowdy(Director)George Rehm(Mr. Rehm is a member of the Board of Managers of the Issuer.)

Board seatRARobert Adelman· per SEC Form D · $4M raise · filed Dec 2015

Tallac Therapeutics is a clinical-stage biopharmaceutical company developing oligonucleotide-based antibody conjugates (TRAAC candidates) designed to deliver immune-activating agents to tumor microenvironments for oncology indications.

BiotechHealthtechMedical DevicesBurlingame, US

HWHong Wan(Executive Officer, Director)in

BoardRan Geng(Director)Michael Carusi(Director)Isaac Cheng(Director)Christine Brennan(Director)

Board seatJPJaume PonsCGCorey Goodman· per SEC Form D

Co-investorsLILightstone VenturesMRMRL Ventures FundMAMatrix Partners ChinaVEvenBio Global Strategic

San Diego, US

Mark S. Forman(Executive Officer)inMatthew Moore(Executive Officer)inJNJohn Nuss(Executive Officer)inJigar Choksey(Director)MAMartin Auster(Executive Officer)inChristopher W. Krueger(Executive Officer)

Board seatARAaron RoystonRGRichard Gaster· per SEC Form D

Co-investorsNENew Science VenturesTHThird Point VenturesWEWellington ManagementSISilverArc PrivateVEvenBio Global Strategic

35Pharma is a biopharmaceutical company developing biologics to treat diseases with high unmet medical need.

BiotechHealthtech

Ilia(CEO)Maureen(CSO)

Co-investorsFRFrazier Life SciencesJAJanus Henderson InvestorsVIVivo Capital

AI & Machine LearningBiotechDigital HealthHealthtech

Co-investorsDEDecheng CapitalSASamsara BioCapitalWEWestlake Village BioPartnersACAccess IndustriesKLKleiner Perkins

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.

BiotechHealthtechMedical Devices

Co-investorsATAtlas VentureFOForesite CapitalFRFrazier Life SciencesGEGeneral AtlanticLILifeSci Venture PartnersSCScion Life Sciences+2 more

Alexion is a biopharmaceutical company focused on research and development of treatments for rare diseases, serving rare disease patients and their families worldwide.

BiotechHealthtechBoston, US

Co-investorsANAndera PartnersCOConnecticut Innovations

Arpeggio Bio is a pharmaceutical company that uses AI and high-throughput RNA-sequencing to develop drugs targeting transcription factors, including historically "undruggable" proteins such as NRF2, TEAD, and GPX4.

AI & Machine LearningBiotechDeep TechHealthtechBoulder, US

JAJoey Azofeifa(Founder)inLNLaura Norris(Executive Officer, Director)inTimothy Read(Executive Officer, Director)Eric Martin(Executive Officer)in

BoardAmit Mehta(Director)

Co-investorsATATEM Capital FundFIFifty YearsFUFundersClubTATau VenturesY Y CombinatorALAlamo Angels+9 more

Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.

AI & Machine LearningBiotechDeep TechHealthtechCambridge, US

MGMichael Gilman(Executive Officer, Director)inMDMark DeLong(CEO)inDNDavid Neafus(Executive Officer)inRussell C. Petter(Executive Officer)

BoardCCColleen Cuffaro(Director)inAEAlan E. Walts(Director)in

Co-investorsCACanaan PartnersPFPfizer VenturesADAdvent Life SciencesHBHBM Healthcare InvestmentsHBHBM PartnersNENextech Invest+2 more

Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings.

BiotechHealthtechMedical DevicesSan Diego, US

Jennifer Bush(Executive Officer)inThomas J. Farrell(Executive Officer)FAFred Aslan(Executive Officer, Director)inJLJason Litten(Executive Officer)inEsther van den Boom(Executive Officer)PFPeter Flynn(Executive Officer)in

Co-investors5A5AM VenturesECEcoR1 CapitalRARA CapitalWEWellington ManagementVEvenBio Global Strategic

Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.

BiotechDigital Health

ZOZaneta Odrowaz(Founder)inTFTao Fu, MBA, M.S.(Founder, Chief Executive Officer, and President)ZOZaneta Odrowaz, Ph.D.(Chief Business Officer and Co-Founder)Petter Veiby(Chief Scientific Officer and Co-Founder)inHangjun Zhan, Ph.D.(Chief Technology Officer and Co-Founder)

Co-investorsECEcoR1 CapitalFRFrazier Life SciencesILIllumina VenturesNENextech InvestSASanofi VenturesVIVida Ventures+1 more

BiotechSan Francisco, US

MPMatthew Patterson(Executive Officer, Director)in

BoardJSJonathan Silverstein(Director)inSSSteve Squinto(Director)inKPKush Parmar(Director)inJLJonathan Leff(Director)Thomas Woiwode(Director)

Co-investorsASAsset Management CompanyHEHercules Capital, Inc.RARA Capital5A5AM VenturesDEDeerfield Management CompanyOROrbiMed+1 more

Aurinia is a biopharmaceutical company developing therapies for autoimmune diseases with significant unmet medical needs.

BiotechDigital HealthHealthtechMedical DevicesVictoria, US

RMRichard M. Glickman(Executive Officer, Director)inStephen W. Zaruby(Executive Officer, Director)MMMichael Martin(Executive Officer, Director)inDennis Bourgeault(Executive Officer)Mr. Tang(Chief Executive Officer and Chair of the Board)

BoardKVKurt von Emster(Director)in

Co-investorsLULumira VenturesNENew Enterprise Associates (NEA)

Axent Biosciences develops stem cell therapies to treat diseases like Parkinson's, using a proprietary cell cultivation platform to enable scalable and cost-effective manufacturing.

BiotechDeep TechHealthtechMedical DevicesNew MaterialsBerkeley, US

David Schaffer(Professor)

Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases.

BiotechHealthtech

PTPraveen Tipirneni(Chief Executive Officer)LWLiangsu Wang(Chief Scientific Officer)ZLZhong Liu(Chief Technology Officer)APAaron Pelta(Chief Business Officer)CWColm White(Chief Program Officer)

Co-investorsATAtlas VentureJAJanus Henderson InvestorsLALAVWEWellington Management

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.

BiotechHealthtechSan Diego, US

KSKen Song(Chairman, President and CEO)inKSKenneth Song, M.D.(Executive Officer, Director)AKArvind Kush(Executive Officer)TLTimothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)

BoardJeffrey Tong, Ph.D.(Director)

Co-investorsFOForesite CapitalLILifeSci Venture PartnersOROrbiMedSASamsara BioCapitalTCTCG CrossoverTHThird Rock Ventures+2 more

Activating the immune system to recognize and destroy tumor cells.

BiotechCambridge, US

Art Krieg(Executive Officer, Director)Barry Labinger(Executive Officer, Director)Chuck Abdalian(Executive Officer)David Mauro(Executive Officer)Karen Brennan(Executive Officer)Charles Yon(Executive Officer)

Co-investorsDEDecheng CapitalF-F-Prime CapitalLOLongitude CapitalSOSofinnova VenturesNONovo Holdings

Entact is a drug discovery company developing treatments for patients.

BiotechDeep TechWatertown, US

Victoria Richon(Executive Officer, Director, Promoter)inRuben Tommasi(Chief Scientific Officer)Michael Gutch(Chief Operating Officer)Alon Lazarus(Director)

BoardAndrew Sinclair(Director)AFAnna French(Director)in

Co-investorsABAbingworthARArkin CapitalQIQiming Venture PartnersVEvenBio Global Strategic

Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.

BiotechHealthtechMedical DevicesNew York, US

Co-investorsBRBrandon CapitalKLKleiner PerkinsNENew Enterprise Associates (NEA)NENextech InvestPRProspect Venture PartnersRHRho Capital Partners+3 more

HistoWiz offers histopathology services for cancer researchers, processing mailed tissue specimens and producing digital whole-slide images accessible through a cloud-based virtual microscope.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSaaSNew York City, US

KCKe Cheng(CEO)inLHLinh Hoang(Chief Executive Officer)inJKJerry Kuang(Chief Operations Officer)JFJulie Feldstein(Chief Pathologist)in

Co-investorsASAsahi Kasei Corporate Venture CapitalNENew York AngelsVIVivo CapitalY Y CombinatorAVAvlok CapitalK5K5 Ventures+1 more

Co-investorsDEDecheng CapitalFOForesite Capital

Impel Pharmaceuticals develops therapies for patients using its drug delivery technology and expertise with small and large molecules.

BiotechHealthtechMedical Devices

Co-investorsCOCowles VenturesNONorwest Venture Partners

Insamo develops an automated platform for drug discovery that designs, synthesizes, and tests cyclic peptides at scale using machine learning and proprietary experimental data.

AI & Machine LearningBiotechDeep TechChippendale, AU

TCTim Craven(CEO)inTPToby Passioura(Founder)inGlen McIntyre(Founder)Timothy Craven(Founder)

BoardCGCOREY GOODMAN(Director)inMHMATT HERSHENSON(Director)in

Co-investorsBEBEVCCICivilization Ventures Management, LlcMRMRL Ventures FundPLPlayground GlobalAXAxial VCVEvenBio Global Strategic

Lyell develops CAR T-cell therapies for cancer patients by leveraging deep expertise in T-cell biology and oncology.

BiotechDeep TechHealthtechMedical DevicesBothell, US

Stan Riddell(Executive Officer)Richard Klausner(Executive Officer, Director, Promoter)Stephen Hill(Executive Officer)inHTHeather Turner(Executive Officer)inRichard Goold(Executive Officer)inMargo Roberts(Executive Officer)

Co-investorsARARCH Venture PartnersFOForesite Capital8V8VCAXAxial VC

MindRhythm develops a portable, non-invasive medical device that uses the Headpulse algorithm and AI to triage stroke patients in the prehospital setting, helping paramedics identify Large Vessel Occlusion strokes and route patients to appropriate hospitals faster.

AI & Machine LearningDeep TechDigital HealthMedical Devices

JKJohn Keane(Co-Founder & CEO)inPLPaul Lovoi(Co-Founder & CTO)inWade Smith(Co-Founder & Chair of the Scientific Advisory Board)

Co-investorsDCDCVC (Data Collective)YOYork IE

Myoventive develops RNA-based medicines to treat genetic heart diseases.

BiotechSouth San Francisco, US

Co-investorsMRMRL Ventures Fund

Neurogastrx is a biopharmaceutical company developing therapies for patients with gastrointestinal disorders.

BiotechHealthtechWoburn, US

CDCyril De Colle(Founder)inJAMES DETORE(Executive Officer)JOJAMES O'MARA(Executive Officer, Director)inPAUL ROGERS(Executive Officer)in

BoardDADAVID ALLISON(Director)inKVKLAUS VEITINGER(Director)in

Co-investors5A5AM VenturesOROrbiMedSASamsara BioCapitalVIVivo CapitalRTRTW Investments L.P.VEvenBio Global Strategic+1 more

NFlection is a biopharmaceutical company developing novel therapeutics.

BiotechMedical DevicesBoston, US

CPChristopher Powala(Chief Development Officer, Former President & CEO)Mark de Souza(Executive Officer, Director)in

BoardCorey Goodman(Director)KPKetan Patel(Director)in

Co-investorsF-F-Prime CapitalVEvenBio Global Strategic

Oak Hill Bio develops therapies for patients with rare diseases, supported by experienced life science investors.

BiotechHealthtechMedical Devices

Pharvaris develops investigational oral therapies for people living with bradykinin-mediated angioedema.

BiotechHealthtech

Co-investorsBABain Capital Life SciencesFOForesite CapitalGEGeneral AtlanticKUKurma PartnersVIViking Global

Portage is a clinical-stage immuno-oncology company developing novel cancer therapies with a portfolio in drug development.

BiotechHealthtechMedical Devices

Queenly is an online marketplace where users can buy and rent formal wear across iOS, Android, and web platforms.

ConsumerDirect to ConsumerE-commerceMarketplacesSan Francisco, US

TBTrisha Bantigue(Founder)inKZKathy Zhou-Patel(Founder)inTBTrisha Bantigue Tsao(Founder)inMengzhou Zhou(Director)Kathy Zhou(Founder)Dewandra Downs(Software Engineer)

Co-investorsALAlumni VenturesAMAmino CapitalGAGaingelsINInterlace VenturesRERebel FundSHSHAKTI+14 more

Regeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease.

BiotechHealthtechTarrytown, US

Co-investorsRIRidgeback CapitalSASanderling VenturesWIWireframe Ventures

Teva Pharmaceuticals is a global pharmaceutical company that discovers, develops, and manufactures medicines to treat chronic conditions for patients across 57 markets.

BiotechHealthtechImpact & Social GoodMedical Devices

Co-investorsBLBlumberg Capital

Verona Pharma develops treatments for chronic lung conditions.

BiotechHealthtechLondon

Jan-Anders Karlsson(Executive Officer, Director)inPSPeter Spargo(Executive Officer)inPatrick Humphrey(Director)Ken Cunningham(Director)Kenneth Newman(Executive Officer)Anders Ullman(Director)

Co-investorsACAccess BiotechnologyAIAisling CapitalANAndera PartnersFOForesite CapitalFRFrazier Life SciencesNENew Enterprise Associates (NEA)+4 more

Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.

BiotechCambridge, US

Andrew Ashe(Executive Officer)SKSekar Kathiresan(Founder)inABAndrew Bellinger(Executive Officer)Kiran Musunuru(Founder)

BoardJohn Evans(Director)APAnthony Philippakis(Director)in

Co-investorsARARCH Venture PartnersF-F-Prime CapitalGVGV (Google Ventures)RARA CapitalWEWellington ManagementCACasdin Capital+3 more

AI & Machine LearningBiotechHealthtech

Co-investorsAVAvoro Capital AdvisorsMEMedicxiTCTCG CrossoverUNUniQuest Extension Fund (UEF)JMJMI Equity